论文部分内容阅读
目的:探讨脑出血保守治疗患者接受单唾液酸四己糖神经节苷脂(博司捷)联合依达拉奉治疗的效果。方法:根据我院的100例脑出血保守治疗患者进行研究分析,将患者分为对照组和观察组,均50例。对照组使用常规治疗和博司捷治疗;观察组增加依达拉奉治疗,两组均接受两周治疗,对两组的NIHSS评分、Barthel指数、hs-CRP水平进行比较分析。结果:两组治疗前各项指标均无统计学差异性(P>0.05);经过治疗,NIHSS评分、Barthel指数、血清hs-CRP水平有所改善,观察组优于对照组,结果存在统计学差异性(P<0.05);观察组有效率为90%,对照组为72%(P<0.05)。结论:脑出血保守治疗使用博司捷联合依达拉奉,使患者的炎性反应显著减轻,日常活动能力改善,其有效率高,效果好,可以推广使用。
Objective: To investigate the effect of conservative treatment of patients with intracerebral hemorrhage treated with monosialotetrahexosyl ganglioside (Bosch) and edaravone. Methods: According to 100 cases of conservative treatment of patients with cerebral hemorrhage in our hospital for research and analysis, the patients were divided into control group and observation group, 50 cases. The patients in the control group received conventional treatment and Bostik. The patients in the observation group were treated with edaravone. Both groups received two weeks of treatment. The NIHSS scores, Barthel index and hs-CRP levels were compared between the two groups. Results: There was no significant difference between the two groups before treatment (P> 0.05). After treatment, NIHSS score, Barthel index and serum hs-CRP level were improved, and the observation group was superior to the control group (P <0.05). The effective rate was 90% in the observation group and 72% in the control group (P <0.05). Conclusions: Conservative treatment of cerebral hemorrhage using Bortezipil and edaravone can significantly reduce the inflammatory response and improve the daily activities of patients with high efficiency and good effect. It can be used widely.